Continuing Legal Education (CLE)

AIPLA CLE Webinar: Medical Device Patent Portfolios – Strategic Considerations for 2019 and Beyond

June 19, 2019 12:30 PM to 2:00 PM (Eastern Daylight Time)

Credits

1.5 CLE Credits

Registration

Fee: $95.00 and Up

Register Now


Development of and regulatory approval for medical devices require investment supported by exclusivity provided by portfolios of patents.  Many of today’s devices are not only mechanical, but include computer-implemented elements or are even Software-as-Medical Devices (SaMD), including artificial intelligence. Please join our speakers to learn of important considerations for patent claiming in a challenging environment for diagnostic and software inventions and, in view of regulatory and enforcement conditions, developing and evaluating, internally or by acquisition, medical device patent portfolios.


Presented by: Justine Gozzi of Baker Botts LLP and Stephen Chow of Hsuanyeh Law Group PC.


 

AIPLA Member Rate

General/Non-Member Rate

Single Site (1 Attendee)

$95**

$195

2-10 Attendees per Site
All attendees must participate at the same location.

$295

$350

11-20 Attendees per Site
All attendees must participate at the same location.

$445

$495

21+ Attendees per Site
All attendees must participate at the same location.

$595

$650

 
Special rate for AIPLA SOLO PRACTICE/SMALL FIRM MEMBERS:  $65

Registration includes:

  • For multiple-attendee sites, all participants must attend at the same location.
  • CLE certification/processing for applicable states.  Reference CLE Information below for complete details.  
  • Webinar materials, including complete CLE processing information, accessible 24-48 hours before webinar date.

Cancellation Policy:

To get full refund, registrant must request refund five (5) days prior to live event. If less than five (5) days, registrant is transferred to product.

System requirements: 

Webinar access is compatible with any Windows 7 or later computer, Android OS devices, or Apple/iOS devices.  Check system compatibility here.

Accessibility for hearing impaired:

AIPLA’s webinars are available and accessible to individuals who are hearing impaired. If anyone at your location would like to know more about accommodations, please contact cle@aipla.org. We ask that you let us know at least 7 business days out from the webinar, to ensure that we can identify and deploy the solution that best fits our registrants needs.


CLE INFORMATION 

AIPLA has sought CLE accredidation* in the following states for credit(s): 

*CLE accredidations updated upon receipt.

Alabama

 Hawaii

Louisiana

Nevada

Oregon

 Virginia

Alaska

 Idaho

Maine

New Jersey

Pennsylvania

Washington

Arkansas

Illinois

Minnesota

New Mexico

Rhode Island

West Virginia

California

Indiana

Mississippi

New York

South Carolina

Wisconsin

Colorado

Iowa

Missouri

North Carolina

Tennessee

 Wyoming

Delaware

Kansas

Montana

North Dakota

Texas

Florida

Kentucky

Nebraska

Ohio

Utah (self-study)

 

Georgia

 

 

 

  

CLE Restrictions: 

ATTENTION attorneys in Louisiana, Ohio, Pennsylvania and Utah
These states mandate attorneys can only view a webinar independently at their own computer to receive CLE credit.  Multiple attendees prohibited.

ATTENTION attorneys in Arizona

Arizona does not certify courses or providers. Arizona lawyers are required to independently review AZ's regulations and make their own determination that it qualifies for credit towards their MCLE requirements. MCLE Regulation 104(A) identifies the standards to apply.  AIPLA will email an attendance affidavit to registrants requesting AZ CLE credit after the webinar.

ATTENTION attorneys in New Hampshire

New Hampshire attendees must self-determine whether a program is eligible for credit, and self-report their attendance according to NH Supreme Court Rule 53.  The New Hampshire Minimum Continuing Legal Education (NHMCLE) Board does not approve or accredit CLE activities for the NH Minimum CLE requirement.  AIPLA will email an attendance affidavit to registrants requesting NH CLE credit after the webinar.   


 Disclaimer:  AIPLA is a nonprofit national bar association.  The sole purpose of this CLE program is to provide educational and informational content.  AIPLA does not provide legal services or advice.  The opinions, views and other statements expressed by contributors to this CLE program are solely those of the contributors.  These opinions, views and statements of the contributors do not necessarily represent those of AIPLA and should not be construed as such.


Add to:

 

 

News

  • PTAB Publishes Update PTAB Publishes Update to AIA Trial Practice Guide

    July 18, 2019

    The US Patent and Trademark Office (USPTO) on July 15, 2019, published a second update to the AIA Trial Practice Guide (TPG) containing additional guidance about trial practice before the Patent Trial and Appeal Board (PTAB).
  • Guide New Examination Guide on Specimen Examination

    July 16, 2019

    The United States Patent & Trademark Office published a new examination guide titled, "Examination of Specimens for Use in Commerce: Digitally Created or Altered and Mockup Specimens."
  • Turbine Engine Federal Circuit Says No Standing for GE Without Specific Injury

    July 15, 2019

    The US Court of Appeals for the Federal Circuit on July 10, 2019, held that General Electric Co.‘s position as a patent owner’s competitor was insufficient to establish standing to appeal a Patent Trial and Appeal Board decision.
  • USPTO Issues Final Rule on Claim Construction Standard PTAB Designates Decision as Precedential

    July 12, 2019

    The US Patent and Trademark Office on July 10, 2019, designated as precedential Focal Therapeutics, Inc. v. SenoRx, Inc., Case IPR2014-00116 (PTAB July 21, 2014) (Paper 19).
  • 20190620_120639411_iOS-400x200 IP Practice in China 2019 Trip

    July 11, 2019

    The IP Practice in China Committee delegation kicked of this year's trip with a dinner with Dennis Duncan, the USPTO IP Attache based in Beijing, who provided a briefing of current developments in China.